INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Cocrystal Pharma, Inc. (formerly BioZone Pharmaceuticals, Inc.) Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Cocrystal Pharma, Inc. investors (Cocrystal or the Company) (NASDAQ: COCP) concerning the Company and its officers possible violations of federal securities laws.

On September 7, 2018, the U.S. Securities and Exchange Commission (SEC) filed a lawsuit against former officers of BioZone as well as other individuals and corporations, alleging violations of the federal securities laws. The SEC complaint alleges that defendants were participants in highly profitable ˜pump-and-dump schemes . . . from 2013 through 2018 in the stock of three public companies, including BioZone, that, while enriching Defendants by millions of dollars, left retail investors holding virtually worthless shares. On this news, Cocrystals share price fell more than 14%, to close at $3.20 on September 7, 2018, thereby injuring investors.

If you purchased Cocrystal securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
[email protected]